ArticleFrontiers in oncology2026
Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osimertinib is the standard adjuvant therapy for resected epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). However, its use is limited by osimertinib-induced interstitial lung disease (Osi-ILD). Case Presentation: We describe the case of a 62-year-old woman with resected stage IIB (pT1cN1M0) EGFR L858R-mutant lung adenocarcinoma who developed grade 2 Osi-ILD, characterized by new bilateral ground-glass opacities on high-resolution computed tomography (HRCT), after 3 months of adjuvant osimertinib therapy. Osimertinib was immediately discontinued, leading to complete symptomatic and radiographic resolution within 8 weeks without corticosteroid therapy. Given the high risk of ILD recurrence upon rechallenge and the suboptimal efficacy of chemotherapy, a multidisciplinary team consensus recommended switching to almonertinib (110 mg once daily). Remarkably, the patient has maintained disease-free survival without ILD relapse for 36 months. Conclusion: This case provides clinical evidence that switching to almonertinib may represent a viable and safe therapeutic strategy, thereby addressing a critical unmet need in the management of resected early-stage EGFR-mutant NSCLC after Osi-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.